Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 7/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249333 | 1.00 | HRH4 (0.44) | HRH4PTPN11HRH3CHRNB2CHRNB4 | |
| SCHEMBL20249322 | 0.84 | HRH4 (0.39) | HRH4CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20249327 | 0.84 | HRH4 (0.39) | HRH4CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL18291191 | 0.83 | PTPN11 (0.39) | PTPN11CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20249316 | 0.82 | HRH4 (0.40) | HRH4HRH3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL20249337 | 0.82 | HRH4 (0.40) | HRH4HRH3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL20249332 | 0.82 | HRH4 (0.37) | HRH4HRH3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL20249328 | 0.82 | HRH4 (0.37) | HRH4HRH3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL20037485 | 0.80 | PTPN11 (0.37) | HRH4PTPN11HRH3CHRNB2CHRNB4 | |
| SCHEMBL20037487 | 0.80 | PTPN11 (0.37) | HRH4PTPN11HRH3CHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | HRH4 1763/4885PTPN11 200/4885HRH3 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.